A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralgia

This study has been completed.
Sponsor:
Information provided by:
Allergan
ClinicalTrials.gov Identifier:
NCT00168441
First received: September 12, 2005
Last updated: May 27, 2011
Last verified: May 2011

September 12, 2005
May 27, 2011
June 2004
June 2005   (final data collection date for primary outcome measure)
Pain score
Same as current
Complete list of historical versions of study NCT00168441 on ClinicalTrials.gov Archive Site
  • Various Quality of Life questionnaires
  • Reduction in area of pain/allodynia
Same as current
Not Provided
Not Provided
 
A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralgia
Not Provided

4-month study including a 30-day baseline phase

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Postherpetic Neuralgia
Drug: Botulinum Toxin Type A
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
117
June 2005
June 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Postherpetic neuralgia for more than 3 months after the healing of a herpes zoster skin rash.

Exclusion Criteria:

  • Previous use of botulinum toxin of any serotype or immunization to any botulinum toxin serotype.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00168441
191622-066
Not Provided
Therapeutic Area Head, Allergan, Inc
Allergan
Not Provided
Not Provided
Allergan
May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP